Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
To learn more about our range of services or to schedule an appointment for a consultation, visit our Columbus locations contact page
Tirzepatide, the dual GIP/GLP-1 agonist, has shown even greater weight loss in head-to-head comparisons
Get Started 200 lbs 36 lbs 6x more weight loss than exercise and diet alone Lose an average of 18% of your body weight 93% kept the weight off for good ** Data based on JourneyMed's patients over the first six months of treatment Better health, every step of the Journey
If you have something in mind, just ask
The medication was approved by the FDA in 1959 for short-term usetypically 12 weeks or lessbecause its stimulant properties can lead to tolerance, dependence, and cardiovascular stress with prolonged use
:max_bytes(150000):strip_icc()/26Q1_WL_oral-sema_newsroom_1920x1008-1dfa18327b724266bed50c36ab0b9d49.jpg)
